Tracers / [225Ac]Ac-3p-C-DEPA-trastuzumab
[225Ac]Ac-3p-C-DEPA-trastuzumab
Also written as [Ac-225]Ac-3p-C-DEPA-trastuzumab
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- trastuzumab immunoconjugate (monoclonal antibody-chelator conjugate)
- Target / mechanism
- —
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | 94.6% | — | 3p-C-DEPA-NCS | 41428153 2025 EJNMMI Radiopharm Chem 3p-C-DEPA-trastuzumab, 3p-C-DEPA-TFP-PEG4-trastuzumab, DOTA-trastuzumab, and macropa-trastuzumab immunoconjugates were radiolabelled using [225Ac]Ac(NO3)3 (2.0 MBq) dissolved in 0.1 M Hydrochloric acid — the RCC was 94.6% for [225Ac]Ac-3p-C-DEPA-trastuzumab |
Need this precursor?We can point you to suppliers for [225Ac]Ac-3p-C-DEPA-trastuzumab, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41428153. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41428153: 'Conjugation of trastuzumab with 3p-C-DEPA-NCS, 3p-C-DEPA-TFP-PEG4, DOTA-NCS, and macropa-NCS yielded immunoconjugates'. Stage set/updated at stage 23 from PMID 41428153: 'Preclinical characterization of 3p-C-DEPA-NCS and 3p-C-DEPA-TFP-PEG4 as potential Actinium-225 bifunctional chelators using DOTA-NCS and macropa-NCS as benchmarks.'.